Licenses drug-delivery technology to biopharmaceutical companies and sells proprietary medicines and auto-injector products for pharmaceutical partners and healthcare providers.
10-K for FY2025, filed Feb 17, 2026As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated…View ↗
We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”)…View ↗
We have commercialized auto-injector products with Teva Pharmaceutical Industries, Ltd. (“Teva”). We have development programs including…View ↗
Our commercial portfolio of proprietary products includes Hylenex®, utilizing rHuPH20, and XYOSTED®, utilizing our auto-injector technology.View ↗
Royalties are the largest stream: partners pay royalties as licensed products sell. Other revenue comes from product sales and collaboration fees, including upfront and milestone payments, bulk enzyme supplies and research services billed monthly.
10-K for FY2025, filed Feb 17, 2026Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit…View ↗
We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii)…View ↗
We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject…View ↗
F-17 advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services.View ↗
In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged…View ↗
10-K for FY2025, filed Feb 17, 2026
FY2025 revenue by product or service ↗$1.4B
10-K for FY2025, filed Feb 17, 2026
$1.4B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Royalties
Licensed
10-K for FY2025, filed Feb 17, 2026 |
62%
FY2022: 55%
|
Royalties, FY2025
$867.8M Sources
|
Licensed |
|
Product sales, net
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
27%
FY2022: 29%
|
Product sales, net, FY2025
$376.4M Sources
|
Sold outright |
|
Revenues under collaborative agreements
|
11%
FY2022: 16%
|
Revenues under collaborative agreements, FY2025
$152.3M Sources
|
Biopharmaceutical companies license technologies and buy bulk enzyme and development work; U.S. wholesale distributors buy Hylenex and XYOSTED and sell them to hospitals, surgery centers, pharmacies and government agencies.
10-K for FY2025, filed Feb 17, 2026We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”)…View ↗
Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE…View ↗
F-17 advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services.View ↗
We sell XYOSTED and Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell Hylenex to hospitals and XYOSTED to…View ↗
Yes. It kept 23 cents of every revenue dollar as net income in FY2025 and turned 46 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
Raises 2026 Financial Guidance Ranges:View ↗
8-K, filed Apr 30, 2026
(c) On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the…View ↗
Growing. Revenue grew 3.2x in 4 years, from $443.3M in FY2021 to $1.4B in FY2025, about 33% a year.
Broader delivery technology portfolio
Halozyme's portfolio has expanded beyond ENHANZE and pressure-assisted injectors: the latest report adds Hypercon's microparticle and Surf Bio's polymer-based concentration technologies for injectable drugs.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 17, 2026As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated…View ↗
The Hypercon technology is an innovative microparticle approach enabling hyperconcentration of monoclonal antibodies, certain complex…View ↗
The Surf Bio technology is an innovative, polymer-enabled approach enabling hyperconcentration SC of monoclonal antibodies, other biologics…View ↗
High-volume auto-injectors
High-volume auto-injectors move from development plans to part of the current platform lineup.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 17, 2026We also support leading pharmaceutical companies by assisting in the development of, and supplying, auto-injector devices and auto-injector…View ↗
The pressure-assisted auto-injector technology is a form of parenteral drug delivery that continues to gain acceptance and demand among the…View ↗
Competes with Alteogen, Amphastar Pharmaceuticals, AbbVie, Perrigo, Lilly, Endo, Pfizer, Tolmar Pharmaceuticals, Verity Pharmaceuticals, Marius Pharmaceuticals, Teva, Viatris, Scandinavian Health, Ypsomed, West Pharmaceutical, and Owen Mumford
10-K for FY2025, filed Feb 17, 2026Our ENHANZE technology may face increasing competition from alternate approaches and/or emerging technologies to deliver medicines SC. For…View ↗
Loading...